Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
by Zacks Equity Research
Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.
AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Is a Beat Likely for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.
Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics
by Zacks Equity Research
Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics
Earnings Preview: Biogen Inc. (BIIB) Q4 Earnings Expected to Decline
by Zacks Equity Research
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $222.31, marking a -1.06% move from the previous day.
Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $224.69 in the latest trading session, marking a +1.89% move from the prior day.
Ionis' (IONS) Partner to Begin New Huntington's Disease Study
by Zacks Equity Research
Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $239.30 in the latest trading session, marking a +1.11% move from the prior day.
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.
Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.
Biogen Inc. (BIIB) Stock Moves -1.02%: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $239.27, marking a -1.02% move from the previous day.
Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
by Zacks Equity Research
Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $244.14, marking a +1.76% move from the previous day.
Biogen Inc. (BIIB) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $239.92, moving -0.03% from the previous trading session.
Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung
by Zacks Equity Research
Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.
4 Biotechs That Could Be Potential Takeover Targets in 2022
by Ekta Bagri
We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.
Dow, S&P Set Fresh All-Time Closing Highs
by Mark Vickery
Value plays look to have dried up during the past few sessions that account for the front end of the Santa Claus Rally.
Biotech Stock Roundup: Regulatory Updates From NVAX, BBIO Down on Drug Failure & More
by Zacks Equity Research
Regulatory and other pipeline updates from NVAX and BBIO are among a few key highlights from the biotech sector during the past week.
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
by Ekta Bagri
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag
by Zacks Equity Research
Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $235.41 in the latest trading session, marking a +0.4% move from the prior day.